Press Release
Wednesday, June 25, 2014

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides Arcolab receives US FDA approval for Imiquimod Cream

Product to be launched immediately
First product approval from its Italian Semi-solids facility

June 25, 2014: Strides Arcolab (BSE: 532531, NSE: STAR) today announced that it has received ANDA approval from the United States Food & Drug Administration (USFDA) for Imiquimod Cream.

According to IMS data, the US market for generic Imiquimod Cream is approximately USD 140 Million.

This is the first product approval from Beltapharm, the Company’s USFDA approved semi-solids facility in Milan, Italy.

The product will be marketed directly by Strides in the US Market.

About Imiquimod Cream

Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (pre-cancerous skin lesions) on the face or scalp, and external genital and perianal warts in patients 12 years and older.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.
Additional information is available at the Company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
</table>
| Mohan Kumar, CEO – Pharma  
+91 80 6784 0748 | Weber Shandwick         |
| Vikesh Kumar +91 80 6784 0827  
Kannan. N: +91 98450 54745 | Kaveri Mandanna: +91 90089 59697  
KMandanna@webershandwick.com |
|                  | Mahesh Nair: +91 98803 76648  
MNair@webershandwick.com      |